The Countermeasures Against Chemical Threats (CounterACT) team are happy to announce the new R21 Program Announcement with a first receipt date of May 30, 2018.
PAR 18-721 (R21) – Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)
In addition to this opportunity, here are the other Funding Opportunities for CounterACT:
- PAR-18-657 (U54) – Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)
- PAR-16-330 (U01) Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)
- PAR-16-331 (U01) Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)